Clinical Trial Update: Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating cetuximab after immunotherapy for head and neck squamous cell carcinoma (including recurrent and metastatic disease) is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)

Snippet

Sponsor: Wake Forest University Health Sciences | Conditions: Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING